145 related articles for article (PubMed ID: 7967421)
1. [Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study].
Schellong G; Hörnig-Franz I; Rath B; Ritter J; Riepenhausen M; Kabisch H; Goldschmitt-Wuttge B; Schmidt P; Niethammer D; Gaedicke G
Klin Padiatr; 1994; 206(4):253-62. PubMed ID: 7967421
[TBL] [Abstract][Full Text] [Related]
2. [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82].
Schellong G; Brämswig J; Ludwig R; Gerein V; Jobke A; Jürgens H; Kabisch H; Stollmann B; Weinel P; Gadner H
Klin Padiatr; 1986; 198(3):137-46. PubMed ID: 3523020
[TBL] [Abstract][Full Text] [Related]
3. [Significance of procarbazine in the chemotherapy of Hodgkin's disease--a report of the Cooperative Therapy Study DAL-HD-85].
Schellong G; Hörnig I; Brämswig J; Bökkerink JP; Steinhoff A; Ludwig R; Niethammer D; Reiter A; von Lengerke HJ; Heinecke H
Klin Padiatr; 1988; 200(3):205-13. PubMed ID: 3062257
[TBL] [Abstract][Full Text] [Related]
4. An approach to reduce treatment and invasive staging in childhood Hodgkin's disease: the sequence of the German DAL multicenter studies.
Schellong G; Brämswig JH; Schwarze EW; Wannenmacher M
Bull Cancer; 1988; 75(1):41-51. PubMed ID: 3282575
[TBL] [Abstract][Full Text] [Related]
5. [Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years].
Dörffel W; Albrecht M; Lüders H; Marciniak H; Parwaresch R; Schwarze EW; Trauzeddel R; Havers W; Henze G; Janka-Schaub G; Mann G; Niemeyer C; Pötter R; Schellong G; Selle B; Treuner J; Rühl U
Klin Padiatr; 1998; 210(4):212-9. PubMed ID: 9743955
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.
Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L
Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937
[TBL] [Abstract][Full Text] [Related]
7. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
[TBL] [Abstract][Full Text] [Related]
8. Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group.
Schellong G
Baillieres Clin Haematol; 1996 Sep; 9(3):619-34. PubMed ID: 8922249
[TBL] [Abstract][Full Text] [Related]
9. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G
Ann Oncol; 1996; 7 Suppl 4():67-72. PubMed ID: 8836413
[TBL] [Abstract][Full Text] [Related]
10. Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Oncol; 2005 Dec; 16(12):1936-40. PubMed ID: 16157620
[TBL] [Abstract][Full Text] [Related]
11. Pediatric Hodgkin's disease: treatment in the late 1990s.
Schellong G
Ann Oncol; 1998; 9 Suppl 5():S115-9. PubMed ID: 9926249
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group.
Schellong G; Brämswig JH; Hörnig-Franz I; Schwarze EW; Pötter R; Wannenmacher M
Ann Oncol; 1994; 5 Suppl 2():113-5. PubMed ID: 8204510
[TBL] [Abstract][Full Text] [Related]
14. Risk adapted combined modality treatment in children with Hodgkin's disease: NCI, Cairo.
El-Badawy S; Aboulnaga S; Abou Gabal A; Mokhless A; Zamzam M; Sidhom I; Ebeid E; Hussein H
J Egypt Natl Canc Inst; 2008 Jun; 20(2):99-110. PubMed ID: 20029465
[TBL] [Abstract][Full Text] [Related]
15. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
[TBL] [Abstract][Full Text] [Related]
16. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
[TBL] [Abstract][Full Text] [Related]
18. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin's disease, clinical stages I, II A-B and IIIA. Results of brief chemotherapy followed by irradiation.
Fermé C; Lepage E; D'Agay MF; Brice P; Castaigne S; Fermand JP; Frija J; Miot C; Brouet JC; Marty M
Nouv Rev Fr Hematol (1978); 1992; 34(3):247-55. PubMed ID: 1383924
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
